Maxwell Biosciences Raises $10.8M in Seed Funding Round
Summary
The round was led by DecentraNet with participation from Star Lake Bioventures, Joseph Ventures, Keiretsu Forum and members of Harvard Business School Angels. The company intends to use the funds to accelerate the development of its innovative platform, recruit and retain talent, pursue clinical trials, and scale up manufacturing capabilities. Led by CEO Joshua McClure, Maxwell Biosciencesis is developing a peptidomimetic drug platform that outputs low-molecular weight compounds that are functionally distinct from macromolecules because of their ability to easily penetrate membranes. The CLAROMER™ brand anti-infectives platform outputs a diverse library of oligomeric structures demonstrated to be well tolerated in animals and to potently disrupt the membranes of a broad spectrum of viruses and other pathogens, as shown in preclinical animal studies and electron micrograph imaging of bacterial, viral and fungal structures after CLAROMER treatment. Maxwell anticipates sharing results from a prioritized study in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) in the second quarter of 2022.
Funding
Review available funding amount, funding date, investors, and linked company information related to Maxwell Biosciences Raises $10.8M in Seed Funding Round in the interactive ISVWorld profile.